Research Article

Pardaxin Promoted Differentiation and Maturation of Leukemic Cells via Regulating TLR2/MyD88 Signal against Cell Proliferation

Wu-Ching Uen,1,2 Chen-Yen Choong,3 Chen-Jei Tai,3,4,5 and Cheng-Jeng Tai6,7

1Department of Hematology and Oncology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
2School of Medicine, Fujen Catholic University, New Taipei City, Taiwan
3Department of Traditional Chinese Medicine, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
4Department of Obstetrics and Gynecology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
5Traditional Herbal Medicine Research Center, Taipei Medical University Hospital, Taipei, Taiwan
6Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
7Division of Hematology and Oncology, Department of Internal Medicine, School of Medical, College of Medicine, Taipei Medical University, Taipei, Taiwan

Correspondence should be addressed to Cheng-Jeng Tai; cjtai@tmu.edu.tw

Received 27 September 2018; Revised 26 December 2018; Accepted 14 January 2019; Published 24 February 2019

Objective. Leukemia is a cancer of the blood cells. Leukemic THP-1 and U937 cells were used in this study as monocytic effectors cells for proliferation responses and macrophage-like cells induction in leukemia. Pardaxin is an antimicrobial peptide isolated from the marine fish species.

Methods. After treatment for 5 days, pardaxin significantly suppressed cell viability and arrested cell cycle at G0/G1 phase in leukemic cells which were evaluated. Results. Pardaxin also induced cell differentiation and maturation of THP-1 and U937 cells into macrophage-like cells with phagocytotic ability. Moreover, pardaxin elevated the expression of MyD88 but not toll-like receptor (TLR)-2 in both leukemic cells. TLR-2 blocking peptide was used to confirm that pardaxin attenuated phagocytotic ability and superoxide anion production in leukemic cells via activating MyD88 protein. Conclusions. These findings suggested that pardaxin has a therapeutic potential for leukemia.

1. Introduction

Antimicrobial peptides (AMPs) have been known to belong to a huge family of peptide molecules that typically contain less than 100 amino acids and they exist in various types of cells in vertebrates and invertebrates. Previous studies have reported that AMPs facilitate human health and reduce the cancer risk [1]. AMPs play crucial roles in innate system, angiogenesis, and anticancer processes [2–4], which specifically target certain proteins on the membrane of cancer cells and induce cell death, thus exhibiting potent toxicity in targeted cancer cells. Therefore, they have the potential to be applied on antitumor therapy [5, 6]. The present study investigates the anticancer role of an AMP pardaxin in leukemic cell lines along with its potential molecular mechanism. Pardaxin (GFFALIPKIISSPLFKTLL-SAVGSALSSSGGQE) is an antimicrobial peptide (AMP) with 33-amino-acids, which is isolated from the marine fish species. Pardaxin shows antibacterial activities and inhibits various cancer cells including canine perianal gland adenomas [7], bladder-associated tumors [8], human fibrosarcoma cells [4], murine fibrosarcoma cells [9], and buccal pouch carcinogenesis [10].

Leukemia is the most common hematological malignancy. Current therapeutic options include chemotherapy, differentiation inducers, and stem cell transplantation. Among these, the strategy of differentiation induction is less toxic and safer than other methods [11, 12]. Additionally, several polysaccharides isolated from edible materials have been reported to stimulate cytokines production and
differentiation of leukemic cells. For example, *Cordyceps sinensis* inhibited proliferation and induced differentiation in leukemic human U937 cells [13], and *Ganoderma lucidum*-derived polysaccharides could induce differentiation of human leukemic THP-1 cells [10]. A line of evidence shows that activators isolated from black soybean [14] and *Poria cocos* [15] exert antileukemic activity via inducing differentiation in U937 and HL-60 leukemic cells. Moreover, an AMPs epinecinn-1 has been found to regulate the toll-like receptor (TLR)-2/MyD88 pathway in RAW264.7 macrophage [16] and exert antitumor activity for leukemic U937 cells [17]. Another AMP, nisin, obtained from lactic acid bacteria has also been reported to suppress leukemic HL-60 cells [18]. However, the effects of pardaxin on regulating human leukemic cells still remained unknown. Leukemia was classified into acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). ALL is a cancer of the lymphoid line of blood cells characterized by the development of large numbers of immature lymphocytes; AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal cells that build up in the bone marrow and blood and interfere with normal blood cells. Moreover, THP-1 is a human acute monocytic leukemia cell line, and U937 is a human myeloid cell line. In this study, we evaluated the effects of pardaxin on cell proliferation and cell differentiation in human leukemic THP-1 and U937 cells.

2. Materials and Methods

2.1. Materials. TLR-2 block peptide was purchased from Novus Biologicals Inc. (Littleton, CO, USA). Trypan blue, RPMI 1640 medium, L-glutamine, and sodium pyruvate were purchased from Gibco (Grand Island, NY, USA). Polymyxin B, nitroblue tetrazolium (NBT), propidium iodide (PI), sodium dodecyl sulfate (SDS), and dimethyl sulfoxide (DMSO) were from Sigma Chemical Co. (St. Louis, MO, USA). Fetal bovine serum (FBS) was from Hyclone (Logan, UT, USA). Human CD11b antibody was purchased from BD Biosciences Pharmingen, San Diego, CA, USA. The TLR-2 antibody and MyD88 antibody were purchased from Santa Cruz Biotechnology Inc. (Burlingame, CA, USA).

2.2. Cell Culture. Human THP-1 cells and U937 leukemic cells were purchased from Bioresource Collection and Research Center (Hsinchu, Taiwan) and were incubated in RPMI 1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, and antibiotics (100 U/mL penicillin and 100 µg/mL streptomycin). For assays of proliferation and differentiation, THP-1 cells (1.5 × 10⁵/mL) were treated with pardaxin dissolved in RPMI 1640 medium for 5 days. The numbers of viable cells were counted by trypan blue dye exclusion after treatment for 1, 3, and 5 days in the direct differentiation induction models [11].

2.3. Assay for Phagocytosis. After 5 days of differentiation induction with pardaxin, the phagocytic activity was assayed [11]. The cells were washed with phosphate-buffered saline and resuspended in medium (8 × 10⁵/mL) at day 5. Subsequently, cells were incubated with yeast (1.0 × 10⁶/mL) at 37°C for 30 minutes. Finally, cells were placed on a glass slide and observed to determine phagocytic activity. Phagocytosis (as a percentage) was quantified by counting the percentage of yeast-containing cells from 200 cells.

2.4. Assay for Superoxide Anion Level. The level of reactive oxygen species was assayed with NBT. In brief, cells (2 × 10⁵/mL) were treated with pardaxin for 5 days, and then cells were collected and resuspended in medium (8 × 10⁵/mL). The cells were then incubated with NBT solution containing 1 mM phorbol myristate acetate at 37°C for 2 hours. NBT is reduced by reactive oxygen species to form blue-black formazan, which was dissolved with dimethyl sulfoxide, and the absorbance value was measured at 570 nm [19, 20]. The level of superoxide anion generation was compared to that of the normal group.

2.5. Assay for Specific Antigen Markers. The specific differentiation marker CD11b in cells was determined by flow cytometric analysis as previously described [11]. In brief, cells (1.0 × 10⁵/mL) were treated with pardaxin for 5 days, and then cells were washed with phosphate-buffered saline and incubated with CD11b antibody for 1 hour. Redundant antibody was removed by washing with phosphate-buffered saline. The expression of CD11b was analyzed by the flow cytometry.

2.6. Western Blot. Cells were lysed in ice-cold lysis buffer containing 20 mM Tris-HCl (pH 7.4), 1% Triton X-100, 0.1% SDS, 2 mM ethylenediaminetetraacetic acid, 10 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 500 mM sodium vanadate, and 10 mg/mL aprotinin overnight. Then, the cell extract was centrifuged (12,000xg for 10 min) to recover the supernatant. The supernatant was taken as the cell extract. The cell protein was resolved on 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred to polyvinylidene fluoride membrane. The membranes were blocked with 5% nonfat dry milk solution for 1 h and incubated overnight with primary antibodies for 4 h; subsequently, the membrane was washed 3 times each for 5 min in phosphate-buffered saline with Tween 20, shaken in a solution of horseradish peroxidase (HRP)-linked secondary antibody for 1 h, and washed 3 more times each for 5 min in PBST. The expressions of proteins were detected by enhanced chemiluminescent reagent (Millipore, Billerica, MA).

2.7. Statistical Analysis. Experimental results were analyzed in triplicate and expressed as means ± standard deviation (SD). The results were subjected to one-way analysis of variance (ANOVA) and Duncan’s multiple range tests and the significance of differences between sample means was calculated. The P value < 0.05 was considered significant difference.
3. Results

3.1. The Effect of Pardaxin on Cell Survival in Leukemic Cells. Cell viability was decreased in 5, 10, 25, or 50 µg/mL pardaxin-treated THP-1 and U937 leukemic cells for 1, 3, and 5 days, and there were no significant differences in pardaxin-treated groups between THP-1 and U937 leukemic cells whether at day 1, day 3, or day 5. These results indicated that pardaxin has the potential to be antileukemic (Figure 1). To understand whether other mechanisms may be involved in the inhibition of pardaxin on leukemic cells, the effect of pardaxin on cell cycle distribution in THP-1 and U937 leukemic cells was evaluated. As shown in Figure 2 and Table 1, the cell cycle was arrested in G0/G1 phase after treatment with 25 µg/mL of pardaxin for 5 days in both THP-1 and U937 leukemic cells, suggesting that pardaxin treatment limited the cell proliferation of leukemic cells.

3.2. The Induction of Pardaxin on Cell Differentiation in Leukemic Cells. Cell differentiation was found in leukemic THP-1 cells while the cell cycle was arrested in G0 phase [11]. Specific cell markers related to macrophage differentiation were determined and showed in Table 2. After 5-day treatment, the expressions of CD11b were significantly increased by pardaxin in leukemic THP-1 cells and U937 cells from 26.8% and 45.4% to 44.3% and 55.9%, respectively.

3.3. The Activation of Leukemic Cells Treated by Pardaxin. Cell maturation and activity of THP-1 and U937 leukemic cells were evaluated in this study, including superoxide anion production and phagocytosis. CD11b is a marker for cell maturation of leukemic cells. As shown in Figure 3, pardaxin treatment promoted cell maturation. Also, superoxide anion level and phagocytotic ability were elevated in both THP-1 and U937 leukemic cells by treatment with pardaxin for 5 days.
3.4. Pardaxin Promoted THP-1 and U937 Leukemic Cells Differentiation via Regulating TLR-2/MyD88 Signals. Toll-like receptor (TLR)-2 has an important role in the activation and maturation of leukemic cells, and MyD88 protein is a downstream molecule in the TLR pathway. The expression of MyD88 was markedly increased after treatment with pardaxin for 5 days in leukemic THP-1 and U937 cells, whereas TLR-2 level was not influenced in each group (Figure 4), revealing that pardaxin induced cell differentiation via promoting MyD88 level in leukemic THP-1 and U937 cells. In order to confirm the mechanism of pardaxin on TLR-2/MyD88 pathway and leukemic cell maturation, TLR-2 block peptide was used to suppress TLR-2 activation and MyD88 expression, and the results demonstrated that pardaxin treatment for 5 days significantly increased MyD88 level in leukemic THP-1 and U937 cells, but this effect was abolished by treatment with TLR-2 blocking peptide (Figure 5). Similar results were found in superoxide anion production and phagocytotic ability in leukemic THP-1 cells (Figure 6) and U937 cells (Figure 7), and the elevations of superoxide anion production and phagocytotic ability by treatment with pardaxin for 5 days were attenuated by TLR-2 blocking peptide treatment in leukemic THP-1 and U937 cells.

4. Discussion

To induce cell differentiation is an important therapeutic method in hematological cancers like leukemia. Tumor cell differentiation ends cancer cells’ immortality, thus stopping the cell growth and proliferation. One approach for treating leukemia is differentiation therapy that outlines
Table 1: The effect of pardaxin on cell cycle in THP-1 and U937 leukemic cells after treatment for 5 days.

| Cell cycle (%) | THP-1 | U937 |
|----------------|-------|------|
|                | G0/G1 | S    | G2/M |
| Blank          | 30.61±2.16<sup>b</sup> | 13.41±0.89<sup>a</sup> | 49.46±1.58<sup>a</sup> |
| Pardaxin (25 μg/mL) | 50.96±1.65<sup>a</sup> | 4.32±0.67<sup>b</sup> | 35.62±1.13<sup>b</sup> |
| Blank          | 44.62±1.13<sup>b</sup> | 4.91±0.78 | 45.79±1.77<sup>a</sup> |
| Pardaxin (25 μg/mL) | 57.76±1.29<sup>a</sup> | 5.85±1.08 | 29.66±1.43<sup>b</sup> |

Results were shown as mean ± SD (n = 3). The significant difference was shown by various letters between blank and pardaxin treatment group (p < 0.05).

![Figure 3: The induction effect of pardaxin on cell differentiation in THP-1 and U937 leukemic cells.](image)

(a) Superoxide anion level (%)
(b) Phagocytotic ability (%)

Table 2: The effect of pardaxin on mature CD marker (CD11b) in THP-1 and U937 leukemic cells after treatment for 5 days.

| CD11b (%) | THP-1 | U937 |
|-----------|-------|------|
| Blank     | 26.8±1.2<sup>b</sup> | 45.4±0.8<sup>b</sup> |
| Pardaxin (25 g/mL) | 44.3±2.2<sup>a</sup> | 55.9±1.4<sup>a</sup> |

Results were shown as mean ± SD (n = 3). The significant difference was shown by various letters between blank and pardaxin treatment group (p < 0.05).

A treatment plan to eliminate maturation blockage and allows cell differentiation to take place [21]. Terminal differentiation induction represents an alternative approach in leukemia treatment, which would generate leukemia cells with limited replicate capacity that ultimately undergoes apoptosis [22]. Numerous compounds have been screened to treat leukemia. For example, differentiation induced all-trans retinoic acid is effective in leukemia therapy [23]. It was found that arsenic trioxide synergizes with all-trans retinoic acid to enhance terminal differentiation, and tyrosine kinase inhibitor gefitinib markedly activates all-trans retinoic acid-induced differentiation of myeloid cell lines [24–26].

Other differentiation inducers of myeloid leukemia cells have been well documented for leukemia therapy, such as 12-O-tetradecanoylphorbol-13-acetate and vitamin D3 [27, 28]. Recently, several peptides have been found to suppress leukemia cancer like THP-1 leukemic cells by inducing plasma membrane damage, including LPSBD0 and LPSBD2 peptides [29]. Epinecindicin-1 peptide also has been found to regulate the toll-like receptor (TLR)-2/MyD88 pathway in RAW264.7 macrophage [16] and exert anticancer activity for leukemia U937 cells [17]. In addition to cell death, cell differentiation was also important in pardaxin-treated THP-1 and U937 cells in present study. The effect of pardaxin on cell differentiation was confirmed by CD11b marker from monocytic phenotypes to macrophage-like cells and the elevated cell adherence percentage. According to phagocytotic ability assay and cell cycle analysis, we suggest that pardaxin promotes the activation and maturation of macrophage-like cells. We found that superoxide anion production and phagocytotic ability were markedly increased and cell cycle was arrested at G0/G1 phase after treating pardaxin for 5 days.

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, which is a heterogeneous disorder...
of hematopoietic progenitor cells. AML arise from the acquisition and accumulation of genetic and/or epigenetic lesions by progenitor hematopoietic cells, resulting in disruption of differentiation and increased proliferation and leading to blast-cell accumulation in the bone marrow/other tissues. At present, the approach for AML therapy is chemotherapy by using a combination of cytotoxic agents that kill highly proliferating cells. There are no changes in the treatment of
A direct effect on the leukemic cells in addition to their known immune activating effect.

5. Conclusion

Our findings suggest that pardaxin induced selecting leukemic cells differentiation into macrophage-like cells with immunostimulatory function, including phagocytic ability and superoxide anion production. The possible clinical impact of using this peptide in patients with monocytic leukemia will need further investigation.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.
Conflicts of Interest
The authors declare there are no conflicts of interest.

Authors’ Contributions
All the authors contributed sufficiently for their participation in the study, as follows: Wu-Ching Uen performed >60% of the biochemical analyses, which thus afford first authorship of this paper. Chen-Yen Choong and Chen-Jei Tai provided pardaxin and were involved in the experimental design and provided significant scientific suggestions and draft corrections before submission. The corresponding author Cheng-Jeng Tai was responsible for financial resources and funds for the project, supervision of the research activities, and submission of the manuscript.

Acknowledgments
This research work and subsidiary spending were supported by the Shin Kong Wu Ho-Su Memorial Hospital (SKH-TMU-106-05) (Taiwan, R.O.C.).

References
[1] N. Rajapakse, W.-K. Jung, E. Mendis, S.-H. Moon, and S.-K. Kim, “A novel anticoagulant purified from fish protein hydrolysate inhibits factor XIIa and platelet aggregation,” Life Sciences, vol. 76, no. 22, pp. 2607–2619, 2005.
[2] G. Wang, B. Mishra, R. F. Epand, and R. M. Epand, “High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments,” Biochimica et Biophysica Acta, vol. 1838, no. 9, pp. 2160–2172, 2014.
[3] H.-N. Huang, V. Rajanbabu, C.-Y. Pan, Y.-L. Chan, J.-Y. Chen, and C.-J. Wu, “Enhanced control of bladder-associated tumors using shrimp anti-lipopolysaccharide factor (SALF) antimicrobial peptide as a cancer vaccine adjuvant in mice,” Marine Drugs, vol. 13, no. 5, pp. 3241–3258, 2015.
[4] T.-C. Huang, J.-F. Lee, and J.-Y. Chen, “Pardaxin, an antimicrobial peptide, triggers caspase-dependent and ROS-mediated apoptosis in HT-1080 cells,” Marine Drugs, vol. 9, no. 10, pp. 1995–2009, 2011.
[5] F. Schweizer, “Cationic amphiphilic peptides with cancer-selective toxicity,” European Journal of Pharmacology, vol. 625, no. 1–3, pp. 190–194, 2009.
[6] J. S. Mader and D. W. Hoskin, “Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment,” Expert Opinion on Investigational Drugs, vol. 15, no. 8, pp. 933–946, 2006.
[7] C. Pan, C. Lin, M. Chiou, C. Y. Yu, J. Chen, and C. Chien, “The antimicrobial peptide pardaxin exerts potent anti-tumor activity against canine perianal gland adenoma,” Oncotarget, vol. 6, no. 4, 2014.
[8] H.-N. Huang, V. Rajanbabu, C.-Y. Pan, Y.-L. Chan, C.-J. Wu, and J.-Y. Chen, “A cancer vaccine based on the marine antimicrobial peptide pardaxin (GE33) for control of bladder-associated tumors,” Biomaterials, vol. 34, no. 38, pp. 10151–10159, 2013.
[9] S.-P. Wu, T.-C. Huang, C.-C. Lin, C.-F. Hui, C.-H. Lin, and J.-Y. Chen, “Pardaxin, a fish antimicrobial peptide, exhibits antitumor activity toward murine fibrosarcoma in Vivo and in Vivo,” Marine Drugs, vol. 10, no. 8, pp. 1852–1872, 2012.
[10] J. W. Hsu, H. C. Huang, S. T. Chen, C. H. Wong, and H. F. Juan, “Ganoderma lucidum Polysaccharides Induce Macrophage-Like Differentiation in Human Leukemia THP-1 Cells via Caspase and p53 Activation,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 358717, 2011.
[11] S.-C. Wu and B.-H. Lee, “Buckwheat polysaccharides exert antiproliferative effects in THP-1 human leukemia cells by inducing differentiation,” Journal of Medicinal Food, vol. 14, no. 1-2, pp. 26–33, 2011.
[12] S. Castaigne, P. Lefebvre, C. Chomienne et al., “Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/mL) in acute promyelocytic leukemia,” Blood, vol. 82, no. 12, pp. 3560–3563, 1993.
[13] Y.-J. Chen, M.-S. Shiao, S.-S. Lee, and S.-Y. Wang, “Effect of Cordyceps sinensis on the proliferation and differentiation of human leukemic U937 cells,” Life Sciences, vol. 60, no. 25, pp. 2349–2359, 1997.
[14] H.-F. Liao, C.-J. Chou, S.-H. Wu, K.-H. Khoo, C.-F. Chen, and S.-Y. Wang, “Isolation and characterization of an active compound from black soybean [Glycine max (L.) Merr.] and its effect on proliferation and differentiation of human leukemic U937 cells,” Anti-Cancer Drugs, vol. 12, no. 10, pp. 841–846, 2001.
[15] Y.-Y. Chen and H.-M. Chang, “Antiproliferative and differentiating effects of polysaccharide fraction from fu-ling (Poria cocos) on human leukemic U937 and HL-60 cells,” Food and Chemical Toxicology, vol. 42, no. 5, pp. 759–769, 2004.
[16] B.-C. Su and J.-Y. Chen, “Antimicrobial peptide epinecidin-1 modulates MyD88 protein levels via the proteasome degradation pathway,” Marine Drugs, vol. 15, no. 11, 2017.
[17] L. Cruz-Chamorro, M. A. Puertollano, E. Puertollano, G. ´A. de Cienfuegos, and M. A. de Pablo, “In vitro biological activities of magainin alone or in combination with nisin,” Peptides, vol. 27, no. 6, pp. 1201–1209, 2006.
[18] J.-Y. Chen, W.-J. Lin, J.-L. Wu, G. M. Her, and C.-F. Hui, “Epinecidin-1 peptide induces apoptosis which enhances anti-tumor effects in human leukemia U937 cells,” Peptides, vol. 30, no. 12, pp. 2365–2373, 2009.
[19] H.-F. Liao, Y.-Y. Chen, Y.-C. Yang, C.-S. Wang, and Y.-J. Chen, “Rice (Oryza sativa L.) inhibits growth and induces differentiation of human leukemic U937 cells through activation of peripheral blood mononuclear cells,” Food and Chemical Toxicology, vol. 44, no. 10, pp. 1724–1729, 2006.
[20] Y. Han, Z. Cui, Y.-H. Li, W.-H. Hsu, and B.-H. Lee, “In vitro and in vivo anticancer activity of pardaxin against proliferation and growth of oral squamous cell carcinoma,” Marine Drugs, vol. 14, no. 1, 2016.
[21] S. Sell, “Leukemia: Stem cells, maturation arrest, and differentiation therapy,” Stem Cell Reviews, vol. 1, no. 3, pp. 197–206, 2005.
[22] M. Konopleva and M. Andreeff, “Targeting the leukemia microenvironment,” Current Drug Targets, vol. 8, no. 6, pp. 685–701, 2007.
[23] Z. Chen, Z.-Y. Wang, and S.-J. Chen, “Acute promyelocytic leukemia: Cellular and molecular basis of differentiation and apoptosis,” Pharmacology & Therapeutics, vol. 76, no. 1-3, pp. 141–149, 1997.
[24] G. B. Zhou, J. Zhang, Z. Y. Wang, S. J. Chen, and Z. Chen, “Treatment of acute promyelocytic leukemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy,” Philosophical Transactions of the Royal Society of London Series B Biological Sciences, vol. 362, no. 1482, pp. 959–971, 2007.
[25] J. Fang, S.-J. Chen, J.-H. Tong, Z.-G. Wang, G.-Q. Chen, and Z.
Chen, “Treatment of acute promyelocytic leukemia with ATRA
and As 2O3: A model of molecular target-based cancer therapy,”
Cancer Biology & Therapy, vol. 1, no. 6, pp. 614–620, 2002.

[26] M. B. Miranda, R. Duan, S. M. Thomas et al., “Gefitinib
potentiates myeloid cell differentiation by ATRA,” Leukemia,
vol. 22, no. 8, pp. 1624–1627, 2008.

[27] S. Y. James, M. A. Williams, A. C. Newland, and K. W.
Colston, “Leukemia cell differentiation: cellular and molecular
interactions of retinoids and vitamin D,” Gene Pharmacology,
vol. 32, no. 1, pp. 143–154, 1999.

[28] D. Kaul and N. Varma, “Molecular mechanism involved in TPA-
induced myelopoietic programming,” Leukemia Research, vol.
23, no. 3, pp. 235–237, 1999.

[29] H.-H. Sung, W.-N. Jane, W.-Y. Kao, P.-Y. Fu, S.-C. Ho, and C.-
W. Yang, “Lipopolysaccharide-binding motif derived peptides
induce cell membrane damages in human lung cancer and
hepatoma cell lines,” International Journal of Peptide Research
and Therapeutics, vol. 21, no. 3, pp. 313–324, 2015.

[30] E. Villamón, J. González-Fernández, E. Such, J. V. Cervera, D.
Gozalbo, and M. Luisa Gil, “Imiquimod inhibits growth and
induces differentiation of myeloid leukemia cell lines,” Cancer
Cell International, vol. 18, no. 15, 2018.

[31] S. Bock, M. S. Murgueitio, G. Wolber, and G. Weindl, “Acute
myeloid leukaemia-derived Langerhans-like cells enhance
Th1 polarization upon TLR2 engagement,” Pharmacological
Research, vol. 105, pp. 44–53, 2016.